Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IRF7 Modulates Inflammatory Pain through upregulating IFNβ in mice

ABSTRACT: Interferon regulatory factors (IRFs) are a family of transcription factors and function primarily in the immune system, which also play critical roles in other biological processes, such as pain. To date little is known about the functions of the interferon regulatory factor 7 (IRF7) involving in pain. Here we investigate the role of IRF7 signaling in nociceptive processing, using RNA interference strategies or pharmacological approaches. We show that the expression level of IRF7 and interferon (IFN) β is upregulated in primary sensory neurons in a mouse model of inflammatory pain.IRF7-IFNβ signal is involved in regulating neuronal hypersensitivity and pro-inflammatory cytokines production. The results identify IRF7-IFNβ signaling as a critical mediator of neuroinflammation that involve in pain development at the level of the primary sensory ganglion. This pathway may be suggested as a potential target for pain management, particularly in orofacial inflammatory pain.

ORGANISM(S): Mus musculus

PROVIDER: GSE289097 | GEO | 2026/02/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EBV latent nuclear antigen EBNA3A modulates IRF3-dependent IFNβ expression

Project description:Epstein-Barr virus (EBV) persistently infects over 90% of the human population and is the causative agent of infectious mononucleosis and human cancers. For the establishment of life-long infection, EBV tampers with the induction of type I interferon (IFN I)-dependent antiviral immunity in the host. How various EBV latency genes help orchestrate this crucial strategy is incompletely defined. Here, we reveal the mechanism by which the EBV nuclear antigen 3A (EBNA3A) inhibits IFNβ induction. Using proximity biotinylation we identify the histone acetyltransferase P300, a member of the IFNβ transcription complex, as a binding partner of EBNA3A. Follow-up experiments further demonstrate that EBNA3A also interacts with the activated IFN-inducing transcription factor IRF3 that collaborates with P300 in the nucleus and both events are mediated by the N-terminal domain of EBNA3A. Mechanistic studies reveal that EBNA3A reduces the binding of IRF3 to the IFNβ promotor, thereby hampering downstream IFN I signaling. These results reveal a novel mechanism by which viral immune evasion takes place.

2025-05-06 | PXD038572 | Pride

Trigeminal activation

Project description:Rat orofacial inflammatory pain model

| PRJEB82703 | ENA

Transcriptional repression of IRF7 by MYC is critical for antiviral immune response in human pDC [GEN2.2]

Project description:Type I interferons (IFN) are crucial mediators of human innate and adaptive immunity and are massively produced from plasmacytoid dendritic cells (pDC). IRF7 is a critical regulator of type I IFN production when pathogens are detected by TLR7/9 in pDC. However, hyperactivation of pDC can cause life-threatening autoimmune diseases. To avoid the deleterious effects of aberrant pDC activation, tight regulation of IRF7 is required. Nonetheless, the detailed mechanisms of how IRF7 transcription is regulated in pDC are still elusive. To this end, we identified the global gene expression changes after stimulation of human primary pDC with the TLR9 agonist CpGB. We identified that the transcription factor MYC is prominently upregulated upon CpGB engagement in pDC. Moreover, when we knocked down MYC in the pDC-like cell line GEN2.2, production of interferon-stimulated genes (ISGs) was dramatically increased and was further enhanced by CpGB. Interestingly, MYC is shown to be recruited to the IRF7 promoter region through interaction with NCOR2/HDAC3 for its repression, and HDAC3 inhibition enhanced IRF7 expression and IFNβ production. Interestingly, activation of TLR9-mediated NF-kB and MAPK and nuclear translocation of IRF7 were greatly enhanced by MYC depletion. Pharmaceutical inhibition of MYC recovered IRF7 expression, further confirming the negative role of MYC in the antiviral response by pDC. Furthermore, the inverse correlation of MYC and IRF7 was validated in psoriasis skin sample datasets. Therefore, our results identify the novel immunomodulatory role of MYC in human pDC and may add to our understanding of aberrant pDC function in autoimmune diseases.

2016-11-30 | GSE70276 | GEO

Transcriptional repression of IRF7 by MYC is critical for antiviral immune response in human pDC [pDC]

2018-06-01 | GSE70277 | GEO

Transcriptional repression of IRF7 by MYC is critical for antiviral immune response in human pDC [ChIP-seq]

2016-11-30 | GSE70275 | GEO

Alternate isoforms of IRF7 Differentially Regulate Interferon Expression

Project description:Interferon Regulatory Factor 7 (IRF7), and its homologue IRF3, are master transcriptional regulators of the innate immune response. IRF7 binds to promoters of interferon beta (IFNb) and several IFNas, as a homodimer or as a heterodimer with IRF3 to drive expression of these type I IFNs, which in turn activate additional signaling pathways to promote expression of anti-viral genes. Here we demonstrate that retention of the first intron within the coding region of IRF7 is highly regulated across immune tissues and in response to viral infection and other immunologic signals. Importantly, retention of this intron generates an alternative translation start site, resulting in a N-terminally extended form of the protein (exIRF7). Using CRISPR gene editing to generate cells that only express exIRF7, or the canonical version of IRF7 (cIRF7), we demonstrate that exIRF7 uniquely activates a program of genes, including IFNb, in response to innate immune triggers. We conclude that alternative splicing of IRF7 is a previously unrecognized mechanisms used by human cells to tune the interferon response to viral infection and other immune challenges.

2025-07-17 | GSE285352 | GEO

DNA-binding of IRF3, IRF5 and IRF7 transcription factors

Project description:The Interferon Regulatory Factors (IRFs) are essential regulators of the innate immune response to viruses. IRFs 3, 5, and 7 drive type-1-interferon and cytokine production in a cell-type and stimulus-specific manner, suggesting regulatory complexity. IRFs 3, 5 and 7 bind DNA as phosphorylation-activated dimers and are classically described as binding a doublet of the canonical IRF binding site: 5'-AANNGAAA-3’. IRF3/5/7 have both common and distinct gene targets and the simple canonical motif does not capture the regulatory complexity of IRF-dependent gene expression. Previous studies, both low and high throughput, have refined our understanding of IRF regulation, yet a systematic comparison of DNA binding preferences for active, dimeric IRF complexes has not been performed. To address this, we designed an IRF-specific, custom protein-binding microarray (PBM) that includes synthetic IRF binding sites as well as type-1-interferon and cytokine promoters. Using constitutively active, phosphomimetic IRF3, 5 and 7 dimers, we find key DNA binding differences for these factors with implications for IRF-dependent gene regulation.

2018-01-12 | GSE109117 | GEO

S-nitrosylation of IRF7 induced by NOS1 expression in Melanoma suppresses anti-tumor immunity

Project description:Endogenous nitric oxide (NO) produced by nitric oxide synthases (NOSs) plays an important immunosuppressive role in the tumor microenvironment. In melanoma, NOS1 expression was increased with tumor progression and correlated with tumor immune escape through inhibition on type I interferon (IFN) signaling. However, the immune regulatory role and its related mechanism of NOS1 and its impacts on immune therapy such as immune checkpoint blockade (ICB) in melanoma is unclear. Here, we found that NOS1 expression induced IRF7 modification by s-nitrosylation at C435 site in mouse (C481 in human), which functionally promotes tumor growth in mouse models. Mechanically, IRF7-C435-SNO inhibited IFNβ transcription under PRR signal activation, leading to disorder in initiation of type I interferons response in melanoma cell. In melanoma mouse model, IRF7-C435-SNO decreased infiltration and activation of CD8 T cells in tumor microenvironment, by reducing antigen presentation processes in tumor cells and inhibits the maturation of DC1. Clinically, high expression of NOS1 correlated with poor survival prognosis and resistance with to ICB anti-tumor therapies in melanoma cases with less immune cell infiltration. Our study suggested that NOS1 expression in melanoma characterizes IFN-I signal disorders in response to innate immune stimulation by IRF7 s-nitrosylation. Targeting NOS1 signaling might benefit for overcome of immune therapeutically resistance particularly in immune cold melanoma phenotype.

2025-10-01 | GSE279140 | GEO

Identification of a FOXO3/IRF7 circuit that limits inflammatory sequelae of antiviral responses

Project description:This SuperSeries is composed of the following subset Series: GSE36241: Identification of a FOXO3/IRF7 circuit that limits inflammatory sequelae of antiviral responses (ChIP-Seq) GSE37051: Identification of a FOXO3/IRF7 circuit that limits inflammatory sequelae of antiviral responses (expression) Refer to individual Series

2012-09-19 | E-GEOD-37052 | biostudies-arrayexpress

Irf7 orchestrates the immunological reaction in cardiomyocytes upon Adar1 deletion

Project description:Adenosine deaminases acting on RNA (Adar1 and Adar2) catalyze I-to-A RNA editing, a post-transcriptional mechanism involved in multiple cellular functions. The role of Adar1-dependent RNA editing in cardiomyocytes (CMs) remains unclear. Here we show that conditional deletion of Adar1 in CMs results in myocarditis progressively evolving into dilated cardiomyopathy and heart failure at only 6 months of age. Adar1 depletion drives activation of interferon signaling genes (ISGs) in the absence of apoptosis and cytokine activation, and reduces the hypertrophic response of CMs upon pressure overload. Interestingly, ablation of the cytosolic sensor MDA5 prevents cardiac ISG activation and delays disease onset, but does not rescue the long-term lethal phenotype elicited by conditional deletion of Adar1. Retention of a single catalytically inactive Adar1 allele in CMs, in combination with MDA5 depletion, however, completely restores the cardiac function and prevents heart failure. Finally, ablation of interferon regulatory factor 7 (Irf7) attenuates the phenotype of Adar1-deficient CMs to a similar extent as MDA5 depletion, highlighting Irf7 as the main regulator of the immune response triggered by lack of Adar1 in CMs.

2022-08-24 | PXD024974 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data